TP53 and cancer: Interestingly, we observed that ARNTL2 not only promotes multiple cancer-promoting pathways, including the hypoxia signaling pathway, KRAS signaling pathway, P53 signaling pathway, and MYC signaling pathway, but it is also extensively involved in immune-related signaling pathways such as the interferon-alpha response, interferon-gamma response, TGF-Beta signaling pathway, IL-2/STAT5 signaling pathway, and IL6/JAK/STAT3 signaling pathway.